Clinical trials: Niraparib
- Drug or intervention Niraparib
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Ovarian Cancer
A Study of Niraparib in Patients With Ovarian Cancer in Clinical Practice
The main aim of this study is to check for side effects from treatment with niraparib. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what…
- Trial name
- NCT05021562
- Testing
- Niraparib
- Where
- Japan
- Volunteers
- 354 people
- Sponsor
- Takeda
Neoplasms
Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)
This study will evaluate the combination of a poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor, niraparib, with the programmed cell death protein 1 (PD-1) inhibitor, dostarlimab in the paediatric population.
- Trial name
- NCT04544995
- Testing
- Niraparib (Tablet for oral suspension), Dostarlimab, Niraparib (Tablet)
- Where
- 2 sites in United Kingdom
- Volunteers
- 47 people
- Sponsor
- GlaxoSmithKline